Jesse Robles
Critical Care Medicine · Chula Vista, CANPI 1780187229
Payments from drug & device makers
Across 160 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$826
- AbbVie$651
- AstraZeneca$333
- Otsuka America Pharmaceutical, Inc.$158
- Boehringer Ingelheim$138
- Lilly USA, LLC$134
- plus $781 from 19 others
What the payments were for
- Food & beverage$3,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $826 |
| AbbVie | 32 | $651 |
| AstraZeneca | 10 | $333 |
| Otsuka America Pharmaceutical, Inc. | 5 | $158 |
| Boehringer Ingelheim | 7 | $138 |
| Lilly USA, LLC | 4 | $134 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $127 |
| Nestle Healthcare Nutrition Inc. | 4 | $94 |
| Eisai Inc. | 5 | $85 |
| Edwards Lifesciences | 2 | $74 |
| Amgen | 5 | $65 |
| Radius Health, Inc. | 2 | $40 |
| Dexcom, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Novartis | 2 | $33 |
| Sumitomo Pharma America, Inc. | 4 | $32 |
| Gilead | 1 | $22 |
| Pfizer | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| GSK | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Biogen | 1 | $16 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,020 in reported general payments places this provider in the 75th percentile of 715 critical care medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 102 | $120,953 |
| OzempicSemaglutide | 74 | $98,475 |
| EliquisApixaban | 72 | $87,782 |
| JardianceEmpagliflozin | 71 | $75,445 |
| TrulicityDulaglutide | 45 | $72,545 |
| RybelsusSemaglutide | 28 | $64,174 |
| FarxigaDapagliflozin Propanediol | 52 | $60,483 |
| EntrestoSacubitril/Valsartan | 28 | $41,582 |
| MyrbetriqMirabegron | 36 | $37,213 |
| GemtesaVibegron | 28 | $28,762 |
| TrintellixVortioxetine Hydrobromide | 27 | $24,005 |
| ProliaDenosumab | 13 | $21,331 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $19,323 |
| Repatha SyringeEvolocumab | 11 | $15,606 |
| UbrelvyUbrogepant | 14 | $14,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $826 | $162,650102 claims |
| Boehringer IngelheimJardiance, Tradjenta | $138 | $88,78787 claims |
| PfizerEliquis | $22 | $87,78272 claims |
| Lilly USA, LLCTrulicity | $134 | $72,54545 claims |
| AstraZenecaFarxiga | $333 | $60,48352 claims |
| NovartisEntresto | $33 | $41,58228 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $32 | $28,76228 claims |
| AmgenProlia | $65 | $21,33113 claims |
| GSKTrelegy Ellipta | $18 | $19,32316 claims |
| AbbVieUbrelvy | $651 | $14,85014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 715 critical care medicine providers in California.
Other critical care medicine in Chula Vista
- Rafael LupercioRedding$14.6M
- Timothy AlbertsonSacramento$7.6M
- Carolyn CalfeeSan Francisco$5M
- Bassam YaghmourOrange$4.4M
- Cedric Franklin RutlandRiverside$3.2M
- Alex HakimLos Angeles$946K
- Praveen AkuthotaSan Diego$841K
- Wael El MaraachliSan Diego$751K
- Stephen RuossStanford$635K
- Bryon QuickOakland$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.